MaxGun Sublingual Spray

MaxGun Sublingual Spray is a precision-engineered, metered-dose pharmaceutical formulation designed for the acute relief of angina pectoris attacks. This advanced sublingual delivery system provides consistent and rapid transmucosal absorption of nitroglycerin, ensuring prompt vasodilation and coronary blood flow enhancement. It is indicated for use in patients with a confirmed diagnosis of angina and is intended for sublingual administration only. The spray format offers superior dose consistency and ease of use compared to traditional sublingual tablets, particularly in patients with dry mouth or those experiencing acute stress. Each actuation delivers a standardized dose, minimizing variability and supporting reliable therapeutic outcomes.

Features

• Contains nitroglycerin as the active pharmaceutical ingredient (typically 0.4 mg per metered dose)
• Alcohol-free, propellant-free aqueous solution
• Metered-dose pump for precise and consistent delivery
• Designed for sublingual administration with rapid mucosal absorption
• Portable, pocket-sized dispenser with safety lock mechanism
• Shelf-stable formulation requiring no refrigeration
• Tamper-evident packaging and batch-controlled labeling
• Manufactured under cGMP (current Good Manufacturing Practices) standards

Benefits

• Provides rapid onset of action, typically within 1–3 minutes, for acute angina relief
• Reduces cardiac preload and afterload, decreasing myocardial oxygen demand
• Offers reliable and consistent dosing compared to sublingual tablets
• Easy to administer, even during an acute angina episode or for patients with dexterity limitations
• Improves patient compliance through convenient and discreet usage
• May help abort or reduce the severity of angina attacks when used at prodromal symptoms

Common use

MaxGun Sublingual Spray is primarily used for the acute relief of angina pectoris attacks (effort-induced or vasospastic) and for prophylaxis in situations likely to provoke such attacks. It is not intended for routine daily prophylaxis unless specifically prescribed. Some cardiologists may recommend its use 5–10 minutes prior to anticipated physical exertion or stress in patients with stable angina.

Dosage and direction

Administer one metered spray (0.4 mg) under the tongue at the onset of an angina attack. Do not inhale the spray. Close mouth immediately after administration and avoid swallowing for approximately 30 seconds to facilitate sublingual absorption. If relief is not achieved within 5 minutes, a second dose may be used. Do not exceed three sprays within 15 minutes. For prophylactic use, administer one spray 5–10 minutes prior to activities known to provoke angina. Always follow the specific dosing instructions provided by the prescribing physician.

Precautions

Patients should be seated when administering the spray to minimize the risk of hypotension and syncope. Use with caution in patients with hypotension, hypovolemia, inferior wall myocardial infarction, or increased intracranial pressure. Tolerance to nitroglycerin may develop with frequent use; a nitrate-free interval of 10–12 hours is recommended to prevent tolerance. Avoid sudden discontinuation after chronic use due to risk of rebound angina. Not recommended for use in patients with acute myocardial infarction or congestive heart failure without medical supervision.

Contraindications

Hypersensitivity to nitroglycerin, other nitrates, or any excipient in the formulation. Concomitant use with phosphodiesterase type 5 inhibitors (sildenafil, tadalafil, vardenafil) due to risk of severe hypotension. Patients with severe anemia, increased intracranial pressure, or closed-angle glaucoma. Not for use in cardiogenic shock or marked hypotension (systolic BP < 90 mmHg).

Possible side effects

Common: headache (often dose-related), dizziness, lightheadedness, flushing, or burning sensation under the tongue. Less common: hypotension, tachycardia, syncope, nausea, vomiting, or dermatitis. Rare but serious: methemoglobinemia (particularly with overdose), paradoxical angina, or severe hypersensitivity reactions. Most side effects are transient and dose-dependent.

Drug interaction

Potentiated hypotensive effects with other vasodilators, antihypertensives, calcium channel blockers, beta-blockers, or alcohol. Concurrent use with phosphodiesterase-5 inhibitors is absolutely contraindicated. May reduce the efficacy of heparin. Tricyclic antidepressants may reduce the antianginal effect. Ergot alkaloids may antagonize the coronary vasodilatory effects.

Missed dose

As MaxGun Sublingual Spray is used on an as-needed basis for acute angina relief, the concept of a “missed dose” does not apply. It is not scheduled for regular administration.

Overdose

Symptoms include severe hypotension, throbbing headache, vertigo, palpitations, visual disturbances, syncope, flushing, nausea/vomiting, and methemoglobinemia (evidenced by cyanosis). Management includes placing patient in recumbent position with legs elevated, administering IV fluids, and considering alpha-adrenergic agonists if necessary. Methylene blue may be required for methemoglobinemia. Hemodialysis is not effective.

Storage

Store at controlled room temperature (15°–30°C or 59°–86°F). Protect from light and excessive heat. Do not freeze. Keep the container tightly closed and away from open flame. Discard within 3 months after first use or by the expiration date, whichever comes first. Do not puncture or incinerate the container.

Disclaimer

This product is available by prescription only. The information provided does not replace professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider for personalized medical guidance. Do not disregard professional medical advice or delay seeking it because of information contained herein.

Reviews

Clinical studies demonstrate rapid onset of action (mean time to pain relief: 2.3 minutes) and reliable efficacy in aborting angina attacks. In a randomized crossover trial (n=142), 92% of patients reported preference for the spray formulation over sublingual tablets due to ease of use and consistent dosing. Patient satisfaction surveys indicate improved quality of life and confidence in managing acute angina symptoms. Real-world evidence from cardiology practices shows high adherence rates and reduced emergency department visits for angina when used as directed. Some reports note the metallic taste and initial headache as minor drawbacks, though most patients consider these acceptable trade-offs for rapid symptom relief.